AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
PR Newswire•27/08/2026•02:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.